{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:31Z","timestamp":1791389011534,"version":"4.3.3"},"reference-count":159,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Over 20 million adults and 6 million children in the United States (US) have asthma, a chronic respiratory disease characterized by airway inflammation, bronchoconstriction, and mucus hypersecretion. Obesity, another highly prevalent disease in the US, is a major risk factor for asthma and a significant cause of diminished asthma control, increased submucosal eosinophilia, and reduced quality of life. A large subgroup of these patients experiences severe symptoms and recurrent exacerbations despite maximal dosage of standard asthma therapies. In the past two decades, the development of biological therapies has revolutionized the field and advanced our understanding of type 2 inflammatory biomarkers. However, patients with obesity and comorbid asthma are not principally considered in clinical trials of biologics. Large landmark cluster analyses of patients with asthma have consistently identified specific asthma phenotypes that associate with obesity but may be differentiated by age of asthma onset and inflammatory cell profiles in sputum. These patterns suggest that biologic processes driving asthma pathology are heterogenous among patients with obesity. The biological mechanisms driving pathology in patients with asthma and comorbid obesity are not well understood and likely multifactorial. Future research needs to be done to elicit the cellular and metabolic functions in the relationship of obesity and asthma to yield the best treatment options for this multiplex condition. In this review, we explore the key features of type 2 inflammation in asthma and discuss the effectiveness, safety profile, and research gaps regarding the currently approved biological therapies in asthma patients with obesity.<\/jats:p>","DOI":"10.3389\/fphar.2023.1315540","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T04:15:10Z","timestamp":1704687310000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity"],"prefix":"10.3389","volume":"14","author":[{"given":"Diya","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta G.","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J. allergy Clin. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"105806","DOI":"10.1016\/j.rmed.2019.105806","article-title":"Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma","volume":"159","author":"Albers","year":"2019","journal-title":"Respir. Med."},{"key":"B4","unstructured":"When asthma is more than just asthma: type 2 inflammation\n            Allergy\n            Asthma Network\n          2023"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO;2-4","article-title":"Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation","volume":"32","author":"Arestides","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"B6","unstructured":"Tezspire (tezepelumab) approved in the US for severe asthma2021"},{"key":"B7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/cea.13841","article-title":"Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts","volume":"51","author":"Azim","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1172\/JCI129697","article-title":"The anti-IgE mAb omalizumab induces adverse reactions by engaging Fc\u03b3 receptors","volume":"130","author":"Balbino","year":"2020","journal-title":"J. Clin. investigation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/rr39","article-title":"Th2 cytokines and asthma: an introduction","volume":"2","author":"Barnes","year":"2001","journal-title":"Respir. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1586\/ers.11.34","article-title":"Asthma-related comorbidities","volume":"5","author":"Boulet","year":"2011","journal-title":"Expert Rev. Respir. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00125-016-3904-9","article-title":"Adipose tissue macrophages: going off track during obesity","volume":"59","author":"Boutens","year":"2016","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.3390\/nu15102254","article-title":"Beyond BMI","volume":"15","author":"Bray","year":"2023","journal-title":"Nutrients"},{"key":"B14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1165\/rcmb.2014-0213OC","article-title":"Effects of chronic intermittent hypoxia on allergen-induced airway inflammation in rats","volume":"52","author":"Broytman","year":"2015","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2003393","DOI":"10.1183\/13993003.03393-2020","article-title":"Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation","volume":"58","author":"Busse","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/JLB.5MR0120-377R","article-title":"Unraveling the connection between eosinophils and obesity","volume":"108","author":"Calco","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"00204-2019","DOI":"10.1183\/23120541.00204-2019","article-title":"Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma","volume":"6","author":"Castro","year":"2020","journal-title":"ERJ Open Res."},{"key":"B19","unstructured":"Asthma and obesity2013"},{"key":"B20","unstructured":"ACIP vaccine administration guidelines for immunization2023"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1B-9B","DOI":"10.1155\/2006\/279435","article-title":"The role of omalizumab in the treatment of severe allergic asthma","volume":"13","author":"Chapman","year":"2006","journal-title":"Can. Respir. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.jaip.2023.05.044","article-title":"Impact of initiating biologics in patients with severe asthma on long-term oral corticosteroids or frequent rescue steroids (GLITTER): data from the international severe asthma registry","volume":"11","author":"Chen","year":"2023","journal-title":"J. allergy Clin. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2165\/00003088-199325020-00003","article-title":"Clinical pharmacokinetics of drugs in obesity. An update","volume":"25","author":"Cheymol","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"B24","first-page":"56","article-title":"Targeted IgE therapy for patients with moderate to severe asthma","volume":"1","author":"Chipps","year":"2004","journal-title":"Biotechnol. Healthc."},{"key":"B25","unstructured":"Understand the type of asthma you have2023"},{"key":"B26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jaad.2007.11.011","article-title":"The effect of weight on the efficacy of biologic therapy in patients with psoriasis","volume":"58","author":"Clark","year":"2008","journal-title":"J. Am. Acad. Dermatology"},{"key":"B27","unstructured":"Reslizumab (intravenous route)\n            ClinicM.\n          2023"},{"key":"B28","unstructured":"Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma (TIDE-asthma)2023"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1111\/all.14956","article-title":"Effect of anti-IL-5 biologics on weight and body mass index","volume":"76","author":"Cusack","year":"2021","journal-title":"Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1183\/13993003.congress-2022.3216","article-title":"Severe asthma in obese patients: what to expect with Mepolizumab?","volume":"60","author":"Da Cunha Fonseca","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18176\/jiaci.0385","article-title":"Benralizumab: a new approach for the treatment of severe eosinophilic asthma","volume":"29","author":"D\u00e1vila Gonz\u00e1lez","year":"2019","journal-title":"J. investigational allergology Clin. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/17476348.2018.1506331","article-title":"The effect of obesity on lung function","volume":"12","author":"Dixon","year":"2018","journal-title":"Expert Rev. Respir. Med."},{"key":"B35","first-page":"67","article-title":"Skin-to-deltoid-muscle distance at three recommended sites for intramuscular vaccination in a population with obesity: an observational study","volume":"136","author":"Doppen","year":"","journal-title":"N. Z. Med. J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.vaccine.2023.03.018","article-title":"When should a longer needle be used for intramuscular injection in obese patients? A combined analysis of New Zealand data","volume":"41","author":"Doppen","year":"","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/DDDT.S250825","article-title":"Tezepelumab as an emerging therapeutic option for the treatment of severe asthma: evidence to date","volume":"15","author":"Dorey-Stein","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40733-021-00078-w","article-title":"Biological therapy for severe asthma","volume":"7","author":"Dragonieri","year":"2021","journal-title":"Asthma Res. Pract."},{"key":"B39","unstructured":"Xolair prices, coupons, and patient assistant programs2023"},{"key":"B40","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1513\/AnnalsATS.201506-377AW","article-title":"The role of type 2 inflammation in the pathogenesis of asthma exacerbations","volume":"12","author":"Dunican","year":"","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B41","unstructured":"About uncontrolled asthma2023"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1753466618808490","DOI":"10.1177\/1753466618808490","article-title":"Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience","volume":"12","author":"Emma","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7861\/clinmedicine.12-5-427","article-title":"Alternative therapies for asthma: are patients at risk?","volume":"12","author":"Ernst","year":"2012","journal-title":"Clin. Med. Lond. Engl."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/ajhp\/zxac058","article-title":"Implications of obesity for drug administration and absorption from subcutaneous and intramuscular injections: a primer","volume":"79","author":"Erstad","year":"2022","journal-title":"Am. J. health-system Pharm. AJHP official J. Am. Soc. Health-System Pharm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma--present in most, absent in many","volume":"15","author":"Fahy","year":"","journal-title":"Nat. Rev. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"602908","DOI":"10.1155\/2013\/602908","article-title":"The asthma phenotype in the obese: distinct or otherwise?","volume":"2013","author":"Farzan","year":"2013","journal-title":"J. allergy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2147\/JAA.S285738","article-title":"Clinical characteristics and management strategies for adult obese asthma patients","volume":"15","author":"Farzan","year":"2022","journal-title":"J. asthma allergy"},{"key":"B48","unstructured":"What is the first step to breathing better2023"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1111\/all.15426","article-title":"The impact of type 2 immunity and allergic diseases in atherosclerosis","volume":"77","author":"Fern\u00e1ndez-Gallego","year":"2022","journal-title":"Allergy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.amepre.2011.10.026","article-title":"Obesity and severe obesity forecasts through 2030","volume":"42","author":"Finkelstein","year":"2012","journal-title":"Am. J. Prev. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"B52","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.anai.2022.01.025","article-title":"Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma","volume":"128","author":"Geng","year":"2022","journal-title":"Ann. allergy, asthma and Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/imj.13166","article-title":"Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry","volume":"46","author":"Gibson","year":"2016","journal-title":"Intern. Med. J."},{"key":"B54","unstructured":"World asthma day 20232023"},{"key":"B55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/rr41","article-title":"Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease","volume":"2","author":"Greenfeder","year":"2001","journal-title":"Respir. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1111\/all.14308","article-title":"Past, present, and future of anti-IgE biologics","volume":"75","author":"Guntern","year":"2020","journal-title":"Allergy"},{"key":"B57","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1165\/rcmb.2012-0031OC","article-title":"Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma","volume":"47","author":"Hacha","year":"2012","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"E877","DOI":"10.1152\/ajpendo.00626.2010","article-title":"Regulation of HIF-1{alpha} activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia","volume":"300","author":"He","year":"2011","journal-title":"Am. J. physiology. Endocrinol. metabolism"},{"key":"B60","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an Expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"B61","doi-asserted-by":"publisher","first-page":"105189","DOI":"10.1016\/j.phrs.2020.105189","article-title":"Why do some asthma patients respond poorly to glucocorticoid therapy?","volume":"160","author":"Henderson","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2000528","DOI":"10.1183\/13993003.00528-2020","article-title":"Treatment options in type-2 low asthma","volume":"57","author":"Hinks","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.rmed.2009.03.008","article-title":"The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update","volume":"103","author":"Holgate","year":"2009","journal-title":"Respir. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.jaci.2011.03.036","article-title":"Obesity and asthma: an association modified by age of asthma onset","volume":"127","author":"Holguin","year":"2011","journal-title":"J. allergy Clin. Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bbi.2023.04.011","article-title":"The role of inflammation in anxiety and depression in the European U-BIOPRED asthma cohorts","volume":"111","author":"Hou","year":"2023","journal-title":"Brain, Behav. Immun."},{"key":"B66","first-page":"61","article-title":"Nonallergic asthma; differential diagnosis and treatment","volume":"83","author":"Hurwitz","year":"1955","journal-title":"Calif. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40264-020-00926-3","article-title":"Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab","volume":"43","author":"Jackson","year":"2020","journal-title":"Drug Saf."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2300819","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry","author":"Jane McDowell","year":"2023","journal-title":"Eur. Respir. J."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e56433","DOI":"10.1371\/journal.pone.0056433","article-title":"TSLP promotes induction of Th2 differentiation but is not necessary during established allergen-induced pulmonary disease","volume":"8","author":"Jang","year":"2013","journal-title":"PloS one"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1149203","DOI":"10.3389\/fimmu.2023.1149203","article-title":"T-helper cells and their cytokines in pathogenesis and treatment of asthma","volume":"14","author":"Ji","year":"2023","journal-title":"Front. Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jaip.2022.02.040","article-title":"An online weight loss intervention for people with obesity and poorly controlled asthma","volume":"10","author":"Johnson","year":"2022","journal-title":"J. allergy Clin. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1378\/chest.130.3.827","article-title":"The effects of body mass index on lung volumes","volume":"130","author":"Jones","year":"2006","journal-title":"Chest"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1038\/s12276-023-01113-x","article-title":"Sensing the oxygen and temperature in the adipose tissues - who's sensing what?","volume":"55","author":"Kang","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41533-020-00194-9","article-title":"Impact of comorbid conditions on asthmatic adults and children","volume":"30","author":"Kaplan","year":"2020","journal-title":"NPJ Prim. care Respir. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2019.05.031","article-title":"Phenotypes and endotypes of adult asthma: moving toward precision medicine","volume":"144","author":"Kaur","year":"2019","journal-title":"J. allergy Clin. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.3390\/jcm11216567","article-title":"An overview on the primary factors that contribute to non-allergic asthma in children","volume":"11","author":"Klain","year":"2022","journal-title":"J. Clin. Med."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2019.PA2753","article-title":"Dupilimab efficacy in patients with uncontrolled, moderate-to-severe asthma by body mass index","volume":"54","author":"Korn","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B78","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/jpm12020165","article-title":"Omalizumab: an optimal choice for patients with severe allergic asthma","volume":"12","author":"Kotoulas","year":"2022","journal-title":"J. personalized Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2567.2011.03413.x","article-title":"Type 2 innate immune responses and the natural helper cell","volume":"132","author":"Koyasu","year":"2011","journal-title":"Immunology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e061476","DOI":"10.1136\/bmjopen-2022-061476","article-title":"Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis","volume":"12","author":"Kulkarni","year":"2022","journal-title":"BMJ open"},{"key":"B81","article-title":"Omalizumab","volume-title":"StatPearls","author":"Kumar","year":"2023"},{"key":"B82","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.anai.2019.03.031","article-title":"Association of antieosinophil therapy with decreased body mass index in patients with severe asthma: a preliminary retrospective analysis","volume":"122","author":"Kuruvilla","year":"","journal-title":"Ann. allergy, asthma and Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"","journal-title":"Clin. Rev. allergy and Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1053\/rmed.2001.1035","article-title":"Chest mechanics in morbidly obese non-hypoventilated patients","volume":"95","author":"Ladosky","year":"2001","journal-title":"Respir. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3390\/pharmaceutics14122753","article-title":"OX40-OX40L inhibition for the treatment of atopic dermatitis-focus on rocatinlimab and amlitelimab","volume":"14","author":"L\u00e9","year":"2022","journal-title":"Pharmaceutics"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e15868","DOI":"10.1097\/MD.0000000000015868","article-title":"Adverse events of benralizumab in moderate to severe eosinophilic asthma: a meta-analysis","volume":"98","author":"Liu","year":"2019","journal-title":"Medicine"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2337\/db22-1033","article-title":"Dual role of caspase 8 in adipocyte apoptosis and metabolic inflammation","volume":"72","author":"Luk","year":"2023","journal-title":"Diabetes"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fphar.2019.01387","article-title":"The intriguing role of interleukin 13 in the pathophysiology of asthma","volume":"10","author":"Marone","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"930862","DOI":"10.3389\/fimmu.2022.930862","article-title":"The therapeutic potential for targeting group 2 innate lymphoid cells in asthma","volume":"13","author":"Matsuyama","year":"2022","journal-title":"Front. Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1590\/s1679-45082014rw2691","article-title":"Obesity and lung function: a systematic review","volume":"12","author":"Melo","year":"2014","journal-title":"Einstein (Sao Paulo, Braz."},{"key":"B91","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/JAA.S295676","article-title":"Real-world experience with benralizumab in patients with severe eosinophilic asthma: a case series","volume":"14","author":"Menzella","year":"2021","journal-title":"J. asthma allergy"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet. Respir. Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am. J. Respir. Crit. care Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jaip.2020.09.014","article-title":"Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy","volume":"9","author":"M\u00fcmmler","year":"2021","journal-title":"J. allergy Clin. Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"A192","DOI":"10.1136\/thorax-2022-BTSabstracts.341","article-title":"P207 the influence of obesity on the clinical outcome of benralizumab treatment in severe eosinophilic asthma a subgroup analysis from the BPAP study","volume":"77","author":"Nanzer","year":"2022","journal-title":"Thorax"},{"key":"B98","volume-title":"Overweight and obesity statistics","year":"2021"},{"key":"B99","article-title":"Heart, lung, and blood Institute","volume-title":"NHLBI obesity education initiative Expert panel on the identification, evaluation, and treatment of obesity in adults (US). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report","year":"1998"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e011857","DOI":"10.1136\/bmjopen-2016-011857","article-title":"Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)","volume":"6","author":"Niven","year":"2016","journal-title":"BMJ open"},{"key":"B101","unstructured":"Study of safety of CSJ117 in participants with moderate to severe uncontrolled asthma ClinicalTrials.gov2021"},{"key":"B102","unstructured":"A treatment option: nucala (mepolizumab)2023"},{"key":"B103","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/NT.0000000000000092","article-title":"Body mass index: obesity, BMI, and health: a critical review","volume":"50","author":"Nuttall","year":"2015","journal-title":"Nutr. today"},{"key":"B104","article-title":"Background on obesity","volume-title":"The Surgeon general's vision for a healthy and fit nation","author":"Office of the Surgeon General (Us)","year":"2010"},{"key":"B105","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11325-019-01892-6","article-title":"Exposure to intermittent hypoxia inhibits allergic airway inflammation in a murine model of asthma","volume":"24","author":"Ohta","year":"2020","journal-title":"Sleep Breath. = Schlaf Atmung"},{"key":"B106","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pulmoe.2018.01.005","article-title":"Severe asthma in obese patients: improvement of lung function after treatment with omalizumab","volume":"25","author":"Oliveira","year":"2019","journal-title":"Pulmonology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pharmthera.2006.07.003","article-title":"Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic","volume":"113","author":"Owen","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5152\/TurkThoracJ.2019.180204","article-title":"Anti-IL-5 biologicals targeting severe late onset eosinophilic asthma","volume":"21","author":"\u00d6zyi\u011fit","year":"2020","journal-title":"Turkish Thorac. J."},{"key":"B109","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/PROM.S146966","article-title":"Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives","volume":"9","author":"Padilla Galo","year":"2018","journal-title":"Patient Relat. outcome Meas."},{"key":"B110","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1874306401408010059","article-title":"Systemic effects of inhaled corticosteroids: an overview","volume":"8","author":"Pandya","year":"2014","journal-title":"open Respir. Med. J."},{"key":"B111","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2147\/JAA.S275039","article-title":"Targeting TSLP in asthma","volume":"15","author":"Parnes","year":"2022","journal-title":"J. asthma allergy"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1753466618810192","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness","volume":"12","author":"Pelaia","year":"","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B113","doi-asserted-by":"publisher","first-page":"4839230","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","volume":"2018","author":"Pelaia","year":"","journal-title":"BioMed Res. Int."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"","journal-title":"Front. physiology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaci.2018.02.004","article-title":"Obesity and asthma","volume":"141","author":"Peters","year":"2018","journal-title":"J. allergy Clin. Immunol."},{"key":"B116","unstructured":"Pharmacoeconomic review report: dupilumab (dupixent): (Sanofi-Aventis Canada inc.): indication: moderate-to-severe atopic dermatitis (AD). Ottawa (ON): Canadian agency for drugs and technologies in health2018"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jaip.2023.01.021","article-title":"Super-responders to biologic treatment in type 2-high severe asthma: passing fad or a meaningful phenotype?","volume":"11","author":"Portacci","year":"2023","journal-title":"J. allergy Clin. Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J. asthma allergy"},{"key":"B119","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/cea.13885","article-title":"Treating severe asthma: targeting the IL-5 pathway","volume":"51","author":"Principe","year":"2021","journal-title":"Clin. Exp. allergy J. Br. Soc. Allergy Clin. Immunol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/WOX.0b013e31821188e0","article-title":"Interleukin-13 signaling and its role in asthma","volume":"4","author":"Rael","year":"2011","journal-title":"World Allergy Organ. J."},{"key":"B121","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s11695-010-0155-6","article-title":"The effects of bariatric surgery on asthma severity","volume":"21","author":"Reddy","year":"2011","journal-title":"Obes. Surg."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/biomedicines9091096","article-title":"The role of dupilumab in severe asthma","volume":"9","author":"Ricciardolo","year":"","journal-title":"Biomedicines"},{"key":"B123","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/jpm12010010","article-title":"Which therapy for non-type(T)2\/T2-Low asthma","volume":"12","author":"Ricciardolo","year":"","journal-title":"J. personalized Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3390\/biomedicines9111684","article-title":"Characterization of T2-low and T2-high asthma phenotypes in real-life","volume":"9","author":"Ricciardolo","year":"","journal-title":"Biomedicines"},{"key":"B125","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1034\/j.1398-9995.2002.23504.x","article-title":"Allergic vs nonallergic asthma: what makes the difference?","volume":"57","author":"Romanet-Manent","year":"2002","journal-title":"Allergy"},{"key":"B126","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.2147\/JIR.S295038","article-title":"Recent insights into the management of inflammation in asthma","volume":"14","author":"Rupani","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.jaip.2023.05.028","article-title":"Comprehensive characterization of difficult-to-treat asthma reveals near absence of T2-low status","volume":"11","author":"Rupani","year":"2023","journal-title":"J. allergy Clin. Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jaci.2008.01.005","article-title":"Increased sputum and bronchial biopsy IL-13 expression in severe asthma","volume":"121","author":"Saha","year":"2008","journal-title":"J. allergy Clin. Immunol."},{"key":"B129","unstructured":"DUPIXENT\u00ae (dupilumab) approved by European Commission as First and only targeted medicine for children as young as six months old with severe atopic dermatitis2023"},{"key":"B130","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3390\/ijerph7020460","article-title":"Trends and stabilization up to 2022 in overweight and obesity in Switzerland, comparison to France, UK, US and Australia","volume":"7","author":"Schneider","year":"2010","journal-title":"Int. J. Environ. Res. public health"},{"key":"B131","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1378\/chest.11-0948","article-title":"Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthma","volume":"141","author":"Scott","year":"2012","journal-title":"Chest"},{"key":"B132","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11882-021-01024-9","article-title":"Obesity, inflammation, and severe asthma: an update","volume":"21","author":"Sharma","year":"2021","journal-title":"Curr. allergy asthma Rep."},{"key":"B133","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/jcb.24678","article-title":"The many faces of asthma in obesity","volume":"115","author":"Sideleva","year":"2014","journal-title":"J. Cell. Biochem."},{"key":"B134","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur. Respir. J."},{"key":"B135","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejim.2018.01.026","article-title":"Factors reducing omalizumab response in severe asthma","volume":"52","author":"Sposato","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/rr40","article-title":"Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists","volume":"2","author":"Steinke","year":"2001","journal-title":"Respir. Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/ACI.0b013e32834eca41","article-title":"Obesity and asthma disease phenotypes","volume":"12","author":"Stream","year":"2012","journal-title":"Curr. Opin. allergy Clin. Immunol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e36631","DOI":"10.1371\/journal.pone.0036631","article-title":"Cluster analysis of obesity and asthma phenotypes","volume":"7","author":"Sutherland","year":"2012","journal-title":"PloS one"},{"key":"B139","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.rmed.2019.02.008","article-title":"Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma","volume":"150","author":"Tariq","year":"2019","journal-title":"Respir. Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.alit.2018.10.004","article-title":"Obesity and severe asthma","volume":"68","author":"Tashiro","year":"2019","journal-title":"Allergology Int. official J. Jpn. Soc. Allergology."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1016\/j.jaip.2023.06.054","article-title":"Long-term weight changes after starting anti-IL-5\/5Ra biologics in severe asthma: the role of oral corticosteroids","volume":"11","author":"Ten Have","year":"2023","journal-title":"J. allergy Clin. Immunol."},{"key":"B142","unstructured":"Paying for TEZSPIRE2023"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s00464-009-0727-5","article-title":"Gastroesophageal reflux-associated aspiration alters the immune response in asthma","volume":"24","author":"Thomas","year":"2010","journal-title":"Surg. Endosc."},{"key":"B144","doi-asserted-by":"publisher","first-page":"P246","DOI":"10.1055\/s-0039-1678228","article-title":"Impact of body mass index on efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma: pooled analysis of the SIROCCO and CALIMA trials","volume":"73","author":"Trudo","year":"2019","journal-title":"Pneumologie"},{"key":"B146","unstructured":"US obesity rates have tripled over the last 60 years\n            Usafacts\n          2023"},{"key":"B147","unstructured":"FDA approves label changes for Asthma Drug Xolair (omalizumab), including describing slightly risk of heart and brain adverse events\n            U.S. Food and Drug Administration\n          2014"},{"key":"B148","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/BTT.S252574","article-title":"Biological therapies in children and adolescents with severe uncontrolled asthma: a practical review","volume":"15","author":"Votto","year":"2021","journal-title":"Biol. targets and Ther."},{"key":"B149","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/JAA.S39119","article-title":"Diagnosis and management of eosinophilic asthma: a US perspective","volume":"7","author":"Walford","year":"2014","journal-title":"J. asthma allergy"},{"key":"B150","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nri.2017.118","article-title":"TH2 cell development and function","volume":"18","author":"Walker","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"101564","DOI":"10.1016\/j.smrv.2021.101564","article-title":"Asthma and obstructive sleep apnoea in adults and children - an up-to-date review","volume":"61","author":"Wang","year":"2022","journal-title":"Sleep. Med. Rev."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1172\/JCI19246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J. Clin. Investig."},{"key":"B154","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet (London, Engl."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/j.ddmec.2012.09.003","article-title":"TSLP: a key regulator of asthma pathogenesis","volume":"9","author":"West","year":"2012","journal-title":"Drug Discov. today. Dis. Mech."},{"key":"B156","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","article-title":"Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis","volume":"118","author":"Whittington","year":"2017","journal-title":"Ann. allergy, asthma and Immunol."},{"key":"B157","unstructured":"Xolair (omalizumab) for allergic asthma\n            XolairH.\n          2023"},{"key":"B158","article-title":"Corticosteroid adverse effects","volume-title":"StatPearls","author":"Yasir","year":"2023"},{"key":"B159","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1186\/s12877-022-03536-z","article-title":"Factors associated with polypharmacy and the high risk of medication-related problems among older community-dwelling adults in European countries: a longitudinal study","volume":"22","author":"Ye","year":"2022","journal-title":"BMC Geriatr."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2147\/JAA.S378062","article-title":"Tezepelumab for patients with severe uncontrolled asthma: a systematic review and meta-analysis","volume":"15","author":"Zoumot","year":"2022","journal-title":"J. asthma allergy"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1315540\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T04:15:19Z","timestamp":1704687319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1315540\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":159,"alternative-id":["10.3389\/fphar.2023.1315540"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1315540","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1315540"}}